Table 3.

The Comparison of Adverse Events Between Two Treatment Groups

AEs	DEB-TACE Group (n=46)	C-TACE Group (n=52)	P value
Acute liver function impairment	3 (6.5%)	3 (5.8%)	0.877
Acute renal insufficiency	1 (2.2%)	0	0.469
Hypoalbuminemia	5 (10.9%)	5 (9.6%)	0.838
Anemia	1 (2.2%)	5 (10.9%)	0.210
Vomiting	15 (32.6%)	11 (21.2%)	0.200
Fever	5 (10.9%)	10 (19.2%)	0.251
Abdominal pain	20 (43.5%)	18 (34.6%)	0.369
Diarrhea	1 (2.2%)	0	0.469
Total	31 (67.4%)	30 (57.7%)	0.323

Abbreviations: AEs, adverse events; DEB-TACE, drug-eluting beads transarterial chemoembolization; C-TACE, conventional transarterial chemoembolization.